Skip to main content
SymBio Pharmaceuticals Limited logo

SymBio Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 4582 ISIN · JP3383050006 T Manufacturing
Open in API
Filings indexed 87 across all filing types
Latest filing 2025-04-21 Share Issue/Capital Cha…
Country JP Japan
Listing T 4582

About SymBio Pharmaceuticals Limited

https://www.symbiopharma.com/en/

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Recent filings

Filing Released Lang Actions
訂正臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document header explicitly states the filing type as "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and references the submission to the Kanto Local Finance Bureau. The content details the resolution by the Board of Directors on March 25, 2025, to issue stock options (new share acquisition rights) to directors and employees. This action falls under corporate financing/capital structure changes, specifically related to employee compensation via equity. In the provided definitions, 'Capital/Financing Update' (CAP) is the most appropriate category for decisions regarding the issuance of stock options or changes in capital structure, as this document details the terms of the issuance (number of rights, exercise price, total value, etc.). It is not a standard Annual Report (10-K), Interim Report (IR), or simple Earnings Release (ER).
2025-04-21 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document header explicitly states the filing type as "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and references the submission to the Kanto Local Finance Bureau. The content details the resolution by the Board of Directors on March 25, 2025, to issue stock options (new share acquisition rights) to directors and employees. This action, involving the issuance of securities/capital structure changes, is typically filed on a specific Japanese regulatory form (like a timely disclosure filing, which often corresponds to a general capital/financing update or a specific regulatory filing category). Given the detailed nature of the stock option issuance terms (issuance price, exercise period, number of shares, etc.), it directly relates to capital structure changes and financing activities. The closest fit among the provided codes is 'Capital/Financing Update' (CAP), as it details the terms of a new issuance of rights related to capital. Although it is a formal regulatory filing, 'CAP' is more specific than the general 'RNS' fallback for this type of corporate action.
2025-04-18 Japanese
訂正有価証券届出書（参照方式）
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and specifically mentions the filing with the "関東財務局長" (Kanto Local Finance Bureau Director) on "2024年12月25日". It details the terms for the issuance of "新株予約権付社債" (Bonds with Stock Acquisition Rights), specifically the "第７回無担保転換社債型新株予約権付社債" (7th Unsecured Convertible Bond with Stock Acquisition Rights). This type of comprehensive filing detailing the terms of a new security issuance, especially one filed with a financial regulator like the Kanto Finance Bureau, corresponds to a registration statement for capital raising activities. Among the provided codes, "CAP" (Capital/Financing Update) is the most appropriate fit for a detailed securities registration statement concerning the issuance of convertible bonds, which is a core financing activity. It is not a general Annual Report (10-K), an Earnings Release (ER), or a simple announcement (RPA/RNS), as it contains the full, detailed terms of the offering.
2025-03-26 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is a Japanese regulatory filing, indicated by the header information (e.g., 【提出書類】 臨時報告書, 【提出先】 関東財務局長, 【提出日】 2025年３月26日). The content explicitly details the results of a shareholder meeting held on March 25, 2025 (2025年３月25日の当社第20期定時株主総会において、決議事項が決議されました). It lists the resolutions passed (election of directors) and the corresponding vote counts (賛成, 反対, 棄権) and approval percentages. This content directly corresponds to the official results from a general meeting of shareholders. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-26 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document header explicitly states the filing type as "臨時報告書" (Extraordinary/Timely Report). The content details the resolution by the Board of Directors on March 25, 2025, to issue stock options (new share acquisition rights) to directors and employees. In the context of Japanese regulatory filings, a report detailing the issuance of stock options, especially when filed promptly after a board resolution, corresponds to a filing related to capital structure changes or financing activities. Given the options, this is a notification regarding the granting of stock options, which falls under 'Capital/Financing Update' (CAP) as it directly impacts the capital structure and involves the issuance of potential new shares. It is not a standard 10-K, AR, or IR, nor is it a simple announcement of a report (RPA/RNS), as it contains the substantive details of the grant. The Japanese equivalent of a filing detailing stock option grants often aligns with disclosures related to capital changes.
2025-03-25 Japanese
訂正有価証券届出書（参照方式）
Capital/Financing Update Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and specifically mentions the filing with the "関東財務局長" (Kanto Local Finance Bureau Director). The content details the terms for the issuance of "新株予約権付社債" (Convertible Bonds with Stock Acquisition Rights), including issuance amount, interest rates, redemption terms, and conversion price adjustments. This structure and content are characteristic of a formal regulatory filing related to the issuance of securities, which aligns best with the definition of a Capital/Financing Update (CAP) or, more broadly, a specific type of regulatory filing. Given the detailed nature of the offering terms for convertible bonds, it is a filing related to capital structure changes/fundraising. However, in the context of standard SEC filings (which this Japanese filing mirrors in function), a registration statement for debt/equity issuance is a core financing document. Since 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes,' this is the most appropriate specific code. It is not a general 'RNS' because it is a highly specific, required registration document for a public offering/placement.
2025-03-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.